Patients available for eGFR analysisb, n
|
39
|
24
|
63
|
eGFR prior to first dose of eculizumab in parent study, mL/min/1.73 m2
|
Mean (SD)
|
30.9 (26.9)
|
29.6 (29.1)
|
30.4 (27.5)
|
Median (range)
|
24.0 (8.4, 128.3)
|
12.0 (10.0, 105.5)
|
22.1 (8.4, 128.3)
|
eGFR at time of discontinuationc, mL/min/1.73 m2
|
Mean (SD)
|
–
|
92.4 (38.6)
|
–
|
Median (range)
|
–
|
92.3 (34.2, 181.5)
|
–
|
eGFR at last follow-up, mL/min/1.73 m2
|
Mean (SD)
|
65.2 (33.1)
|
85.9 (31.8)
|
73.1 (33.9)
|
Median (range)
|
59.5 (14.8, 152.2)
|
75.6 (40.0, 153.5)
|
65.7 (14.8, 153.5)
|
Patients on dialysis prior to first dose of eculizumab in parent study, n/N (%)
|
18/51 (35.3)
|
17/35 (48.6)
|
35/86 (40.7)
|
Patients on dialysis at last follow-up, n/N (%)
|
2/51 (3.9)
|
5/35 (14.3)
|
7/86 (8.1)
|